CBAY

CymaBay Therapeutics, Inc. [CBAY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CBAY Stock Summary

Top 10 Correlated ETFs

CBAY


Top 10 Correlated Stocks

CBAY


In the News

07:11 29 Mar 2024 CBAY

CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates

CymaBay Therapeutics Inc. (CBAY) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago.

01:55 29 Mar 2024 CBAY

Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion

Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.

11:09 29 Mar 2024 CBAY

Why is CymaBay (CBAY) Stock Up 25% Today?

CymaBay (NASDAQ: CBAY ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company announced an acquisition agreement with Gilead Sciences (NASDAQ: GILD ). That deal has Gilead Sciences agreeing to acquire CymaBay for $4.3 billion.

09:33 29 Mar 2024 CBAY

Gilead to buy CymaBay Therapeutics for $4.3 billion

CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.50 per share.

08:42 29 Mar 2024 CBAY

Drugmaker Gilead to acquire CymaBay for $4.3 bln

Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.

08:42 29 Mar 2024 CBAY

Gilead strikes deal to acquire CymaBay for $4.3 billion

Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for a total deal equity value of $4.3 billion. CymaBay's lead asset is seladelpar, an investigational treatment for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.

08:00 29 Mar 2024 CBAY

CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024

NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.

08:00 29 Mar 2024 CBAY

CymaBay Therapeutics to Present at Upcoming Investment Conferences

NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9t h in Miami Beach, FL, the Piper Sandler 35th Annual Healthcare Conference, November 28-30th, in New York, NY, and the Evercore ISI 6th Annual HealthCONx Conference, November 28-30th, in Miami, Florida.

04:05 29 Mar 2024 CBAY

CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update.

10:34 29 Mar 2024 CBAY

CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable

CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CBAY Financial details

Company Rating
Neutral
Market Cap
3.73B
Income
-111.68M
Revenue
31.07M
Book val./share
2.58
Cash/share
3.48
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-24.35
Forward P/E
-26.84
PEG
11.76
P/S
89.4
P/B
7.92
P/C
9.33
P/FCF
-43.2
Quick Ratio
22.31
Current Ratio
22.76
Debt / Equity
0.37
LT Debt / Equity
0.34
-
-
EPS (TTM)
-1.08
EPS next Y
-1.21
EPS next Q
-0.4
EPS this Y
-27.21%
EPS next Y
12.05%
EPS next 5Y
-359.01%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
8.82%
-
-
-
-
SMA20
-
SMA50
33.33%
SMA100
100%
Inst Own
82.57%
Inst Trans
0.87%
ROA
-24%
ROE
-74%
ROC
-0.19%
Gross Margin
100%
Oper. Margin
-267%
Profit Margin
-342%
Payout
-
Shs Outstand
114.79M
Shs Float
96.64M
-
-
-
-
Target Price
-
52W Range
7.261-32.5
52W High
+1.5%
52W Low
+364%
RSI
82
Rel Volume
-
Avg Volume
3.94M
Volume
Perf Week
0.06%
Perf Month
1.12%
Perf Quarter
131.83%
Perf Half Y
119.02%
-
-
-
-
Beta
0.32
-
-
Volatility
0%, 0.12%
Prev Close
0%
Price
32.48
Change
0%

CBAY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.29
Net income per share
-1.53-0.71-1.31-1.36-0.99
Operating cash flow per share
-1.46-0.65-0.98-0.96-0.68
Free cash flow per share
-1.47-0.65-0.98-0.96-0.69
Cash per share
2.852.122.631.553.71
Book value per share
2.782.071.880.412.75
Tangible book value per share
2.782.071.880.412.75
Share holders equity per share
2.782.071.880.412.75
Interest debt per share
0.030.030.761.211.21
Market cap
131.38M395.45M239.52M549.28M2.51B
Enterprise value
108.67M369M165.3M619.91M2.42B
P/E ratio
-1.29-8.13-2.59-4.62-23.81
Price to sales ratio
000080.73
POCF ratio
-1.34-8.84-3.45-6.53-34.59
PFCF ratio
-1.34-8.84-3.45-6.52-34.37
P/B Ratio
0.712.771.815.198.58
PTB ratio
0.712.771.815.198.58
EV to sales
000077.77
Enterprise value over EBITDA
-1.11-6.91-1.91-6.81-23.93
EV to operating cash flow
-1.11-8.25-2.38-7.37-33.32
EV to free cash flow
-1.11-8.25-2.38-7.36-33.11
Earnings yield
-0.78-0.12-0.39-0.22-0.04
Free cash flow yield
-0.75-0.11-0.29-0.15-0.03
Debt to equity
0.010.010.392.510.37
Debt to assets
0.010.010.250.640.25
Net debt to EBITDA
0.230.50.86-0.780.91
Current ratio
11.5115.3810.418.9410.96
Interest coverage
00-33.91-6.25-5.37
Income quality
0.950.880.770.790.69
Dividend Yield
0000.050
Payout ratio
000-0.210
Sales general and administrative to revenue
00001.67
Research and developement to revenue
00002.58
Intangibles to total assets
00000
Capex to operating cash flow
00000.01
Capex to revenue
0000-0.01
Capex to depreciation
-0.55-0.03-0.13-0.21-0.65
Stock based compensation to revenue
00000.49
Graham number
9.775.747.433.557.84
ROIC
-0.56-0.34-0.48-0.82-0.25
Return on tangible assets
-0.5-0.32-0.46-0.84-0.24
Graham Net
2.571.971.650.342.37
Working capital
185.29M141.73M172.73M122.63M366.96M
Tangible asset value
186.35M142.71M132.94M36.15M292.26M
Net current asset value
183.54M140.47M121.72M32.38M261.37M
Invested capital
0.010.010.392.510.37
Average receivables
343.5K482K138.5K00
Average payables
2.24M1.37M1.48M1.91M2.46M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
1.14K133.411.45K563.442.05K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.322.740.250.650.18
Inventory turnover
00000
ROE
-0.55-0.34-0.7-3.29-0.36
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.3200
Net income per share
-0.42-0.36-0.01-0.34-0.37
Operating cash flow per share
-0.220.07-0.26-0.26-0.24
Free cash flow per share
-0.220.06-0.26-0.26-0.24
Cash per share
1.562.412.194.353.48
Book value per share
0.421.061.113.232.58
Tangible book value per share
0.421.061.113.232.58
Share holders equity per share
0.421.061.113.232.58
Interest debt per share
1.091.021.070.991.01
Market cap
545.59M854.31M1.07B1.51B2.68B
Enterprise value
616.22M890.32M1.13B1.34B2.58B
P/E ratio
-3.75-6.09-330.38-11.11-15.97
Price to sales ratio
0034.43046.96K
POCF ratio
-29.09132.84-41.98-57.58-97.76
PFCF ratio
-29.07137-41.86-57.58-97.12
P/B Ratio
15.098.29.854.629.16
PTB ratio
15.098.29.854.629.16
EV to sales
0036.49045.34K
Enterprise value over EBITDA
-27.32-36.83281.5-41.48-60.9
EV to operating cash flow
-32.85138.44-44.5-51.1-94.4
EV to free cash flow
-32.83142.77-44.38-51.1-93.78
Earnings yield
-0.07-0.040-0.02-0.02
Free cash flow yield
-0.030.01-0.02-0.02-0.01
Debt to equity
2.510.910.920.320.37
Debt to assets
0.640.390.440.230.25
Net debt to EBITDA
-3.13-1.4915.955.262.17
Current ratio
8.945.2212.5222.7610.96
Interest coverage
-5.76-6.1-0.026.65-8.36
Income quality
0.7-0.2231.480.770.65
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000.370347.47
Research and developement to revenue
000.630398.12
Intangibles to total assets
00000
Capex to operating cash flow
0-0.03000.01
Capex to revenue
0000-3.16
Capex to depreciation
-0.07-0.98-0.330-3.21
Stock based compensation to revenue
000.11081.91
Graham number
1.982.930.464.944.63
ROIC
-0.25-0.160-0.07-0.1
Return on tangible assets
-0.26-0.140-0.08-0.1
Graham Net
0.340.970.983.112.22
Working capital
122.63M196.22M206.18M427.99M366.96M
Tangible asset value
36.15M104.19M108.41M326.19M292.26M
Net current asset value
32.38M101.59M105.83M322.8M261.37M
Invested capital
2.510.910.920.320.37
Average receivables
00000
Average payables
787.5K1.36M3.11M3.66M3.28M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
533.19738.541.96K1.14K6.15K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.170.120.050.080.01
Inventory turnover
00000
ROE
-1.01-0.34-0.01-0.1-0.14
Capex per share
00000

CBAY Frequently Asked Questions

What is CymaBay Therapeutics, Inc. stock symbol ?

CymaBay Therapeutics, Inc. is a US stock , located in Newark of Ca and trading under the symbol CBAY

What is CymaBay Therapeutics, Inc. stock quote today ?

CymaBay Therapeutics, Inc. stock price is $32.48 today.

Is CymaBay Therapeutics, Inc. stock public?

Yes, CymaBay Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap